Efavirenz is a highly effective HIV-1 antiretroviral; however, it is also frequently associated
with neuropsychiatric adverse events (NPAE) that include abnormal dreams, sleep …

Although tuberculosis is largely a curable disease, it remains a major cause of morbidity and
mortality worldwide. Although the standard 6-month treatment regimen is highly effective for …

Contamination is a potential problem in the study of ancient proteins, either from prior
handling of the sample, laboratory consumables, or cross-sample carryover from mass …

Background In patients co-infected with HIV and tuberculosis, antiretroviral therapy options
are limited due to drug—drug interactions with rifampicin. A previous phase 2 trial indicated …

Aims Genetic factors, notably CYP2B6 516G→ T [rs3745274] and 983T→ C [rs28399499],
explain much of the interindividual variability in efavirenz pharmacokinetics, but data from …

The World Health Organization guidelines recommend that individuals living with HIV
receive≥ 6 months of isoniazid preventive therapy, including pregnant women. Yet, plasma …

Background Efavirenz (EFV) is used as part of a highly active antiretroviral therapy (ART)
regimen (HAART) against HIV-1 infection 1, 2. It is important to achieve the correct dosage of …

Purpose: The implementation of genomic-based medicine is hindered by unresolved
questions regarding data privacy and delivery of interpreted results to health-care …

There is an urgent need for new antituberculosis (anti-TB) drugs, including agents that are
safe and effective with concomitant antiretrovirals (ARV) and first-line TB drugs. PA-824 is a …

Efavirenz (EFV) is an anti-retroviral drug frequently combined with isoniazid (INH) to treat
HIV-1/tuberculosis co-infected patients. Both drugs have been associated with idiosyncratic …